Literature DB >> 31375579

Murine Cytomegalovirus Infection of Melanoma Lesions Delays Tumor Growth by Recruiting and Repolarizing Monocytic Phagocytes in the Tumor.

Nicole A Wilski1, Christina Del Casale1, Timothy J Purwin2, Andrew E Aplin2,3, Christopher M Snyder4,3.   

Abstract

Cytomegalovirus (CMV) is a ubiquitous betaherpesvirus that infects many different cell types. Human CMV (HCMV) has been found in several solid tumors, and it has been hypothesized that it may promote cellular transformation or exacerbate tumor growth. Paradoxically, in some experimental situations, murine CMV (MCMV) infection delays tumor growth. We previously showed that wild-type MCMV delayed the growth of poorly immunogenic B16 melanomas via an undefined mechanism. Here, we show that MCMV delayed the growth of these immunologically "cold" tumors by recruiting and modulating tumor-associated macrophages. Depletion of monocytic phagocytes with clodronate completely prevented MCMV from delaying tumor growth. Mechanistically, our data suggest that MCMV recruits new macrophages to the tumor via the virus-encoded chemokine MCK2, and viruses lacking this chemokine were unable to delay tumor growth. Moreover, MCMV infection of macrophages drove them toward a proinflammatory (M1)-like state. Importantly, adaptive immune responses were also necessary for MCMV to delay tumor growth as the effect was substantially blunted in Rag-deficient animals. However, viral spread was not needed and a spread-defective MCMV strain was equally effective. In most mice, the antitumor effect of MCMV was transient. Although the recruited macrophages persisted, tumor regrowth correlated with a loss of viral activity in the tumor. However, an additional round of MCMV infection further delayed tumor growth, suggesting that tumor growth delay was dependent on active viral infection. Together, our results suggest that MCMV infection delayed the growth of an immunologically cold tumor by recruiting and modulating macrophages in order to promote anti-tumor immune responses.IMPORTANCE Cytomegalovirus (CMV) is an exciting new platform for vaccines and cancer therapy. Although CMV may delay tumor growth in some settings, there is also evidence that CMV may promote cancer development and progression. Thus, defining the impact of CMV on tumors is critical. Using a mouse model of melanoma, we previously found that murine CMV (MCMV) delayed tumor growth and activated tumor-specific immunity although the mechanism was unclear. We now show that MCMV delayed tumor growth through a mechanism that required monocytic phagocytes and a viral chemokine that recruited macrophages to the tumor. Furthermore, MCMV infection altered the functional state of macrophages. Although the effects of MCMV on tumor growth were transient, we found that repeated MCMV injections sustained the antitumor effect, suggesting that active viral infection was needed. Thus, MCMV altered tumor growth by actively recruiting macrophages to the tumor, where they were modulated to promote antitumor immunity.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  cytomegalovirus; immunomodulation; immunotherapy; macrophages; melanoma

Mesh:

Year:  2019        PMID: 31375579      PMCID: PMC6798091          DOI: 10.1128/JVI.00533-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  103 in total

1.  Survival in patients with glioblastoma receiving valganciclovir.

Authors:  Cecilia Söderberg-Nauclér; Afsar Rahbar; Giuseppe Stragliotto
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

2.  Latent murine cytomegalovirus infection in macrophages.

Authors:  J L Pollock; R M Presti; S Paetzold; H W Virgin
Journal:  Virology       Date:  1997-01-06       Impact factor: 3.616

3.  Mechanism of tumor remission by cytomegalovirus in a murine lymphoma model: evidence for involvement of virally induced cellular interleukin-15.

Authors:  Katja C Erlach; Matthias J Reddehase; Jürgen Podlech
Journal:  Med Microbiol Immunol       Date:  2015-03-25       Impact factor: 3.402

4.  NF-kappaB and phosphatidylinositol 3-kinase activity mediates the HCMV-induced atypical M1/M2 polarization of monocytes.

Authors:  Gary Chan; Elizabeth R Bivins-Smith; M Shane Smith; Andrew D Yurochko
Journal:  Virus Res       Date:  2009-05-07       Impact factor: 3.303

5.  Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans.

Authors:  A B Bigley; K Rezvani; N Shah; T Sekine; N Balneger; M Pistillo; N Agha; H Kunz; D P O'Connor; C M Bollard; R J Simpson
Journal:  Clin Exp Immunol       Date:  2016-08       Impact factor: 4.330

6.  Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound.

Authors:  Afam A Okoye; Scott G Hansen; Mukta Vaidya; Yoshinori Fukazawa; Haesun Park; Derick M Duell; Richard Lum; Colette M Hughes; Abigail B Ventura; Emily Ainslie; Julia C Ford; David Morrow; Roxanne M Gilbride; Alfred W Legasse; Joseph Hesselgesser; Romas Geleziunas; Yuan Li; Kelli Oswald; Rebecca Shoemaker; Randy Fast; William J Bosche; Bhavesh R Borate; Paul T Edlefsen; Michael K Axthelm; Louis J Picker; Jeffrey D Lifson
Journal:  Nat Med       Date:  2018-08-06       Impact factor: 53.440

7.  Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells.

Authors:  Peihong Dai; Weiyi Wang; Ning Yang; Cristian Serna-Tamayo; Jacob M Ricca; Dmitriy Zamarin; Stewart Shuman; Taha Merghoub; Jedd D Wolchok; Liang Deng
Journal:  Sci Immunol       Date:  2017-05-19

8.  HCMV activates the IL-6-JAK-STAT3 axis in HepG2 cells and primary human hepatocytes.

Authors:  Quentin Lepiller; Wasim Abbas; Amit Kumar; Manoj K Tripathy; Georges Herbein
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

Review 9.  Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme.

Authors:  Andrea Schuessler; David G Walker; Rajiv Khanna
Journal:  Front Oncol       Date:  2014-10-07       Impact factor: 6.244

10.  Latent Cytomegalovirus Infection in Female Mice Increases Breast Cancer Metastasis.

Authors:  Zelei Yang; Xiaoyun Tang; Guanmin Meng; Matthew G K Benesch; Martina Mackova; Ana Paula Belon; Jesus Serrano-Lomelin; Ing Swie Goping; David N Brindley; Denise G Hemmings
Journal:  Cancers (Basel)       Date:  2019-03-29       Impact factor: 6.639

View more
  5 in total

1.  STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity.

Authors:  Nicole A Wilski; Colby Stotesbury; Christina Del Casale; Brian Montoya; Eric Wong; Luis J Sigal; Christopher M Snyder
Journal:  J Immunol       Date:  2020-04-13       Impact factor: 5.422

2.  Murine Cytomegalovirus Infection of Melanoma Lesions Delays Tumor Growth by Recruiting and Repolarizing Monocytic Phagocytes in the Tumor.

Authors:  Nicole A Wilski; Christina Del Casale; Timothy J Purwin; Andrew E Aplin; Christopher M Snyder
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 3.  From Vaccine Vector to Oncomodulation: Understanding the Complex Interplay between CMV and Cancer.

Authors:  Nicole A Wilski; Christopher M Snyder
Journal:  Vaccines (Basel)       Date:  2019-07-09

4.  Hematopoietic cell-mediated dissemination of murine cytomegalovirus is regulated by NK cells and immune evasion.

Authors:  Shunchuan Zhang; Lauren E Springer; Han-Zhi Rao; Renee G Espinosa Trethewy; Lindsey M Bishop; Meaghan H Hancock; Finn Grey; Christopher M Snyder
Journal:  PLoS Pathog       Date:  2021-01-28       Impact factor: 6.823

Review 5.  Tumor Control by Cytomegalovirus: A Door Open for Oncolytic Virotherapy?

Authors:  Georges Herbein; Zeina Nehme
Journal:  Mol Ther Oncolytics       Date:  2020-03-29       Impact factor: 7.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.